The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of BLU-285, a novel, potent inhibitor of Exon 17 Mutant KIT and PDGFRA D842V, in patient-derived xenograft model of gastrointestinal stromal tumor (GIST).
 
Yemarshet Kelemework Gebreyohannes
No Relationships to Disclose
 
Madelina-Elena Zhai
No Relationships to Disclose
 
Agnieszka Wozniak
Honoraria - Boehringer Ingelheim
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Jasmien Wellens
No Relationships to Disclose
 
Jasmien Cornillie
No Relationships to Disclose
 
Erica Evans
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
Patents, Royalties, Other Intellectual Property - Blueprint Medicines
 
Alexandra K. Gardino
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Blueprint Medicines
 
Nancy E. Kohl
Employment - Blueprint Medicines
Stock and Other Ownership Interests - Merck
 
Maria Debiec-Rychter
No Relationships to Disclose
 
Raf Sciot
No Relationships to Disclose
 
Patrick Schöffski
Honoraria - Daiichi Sankyo; Medpace
Consulting or Advisory Role - Adaptimmune (Inst); Amcure (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Cristal Therapeutics (Inst); Eisai (Inst); Novartis (Inst); Philogen (Inst); Pique (Inst); Swedish Orphan Biovitrum (Inst)
Speakers' Bureau - Bayer; Eisai; GlaxoSmithKline; Lilly; Novartis; Swedish Orphan Biovitrum
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); CoBioRes NV (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - PharmaMar